Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | AGXT | P21549 | 2/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29271362 | 0.98 | PDE4B (0.51) | PDE4BROCK2NTRK1NAMPTIDO1 | |
| Hydrochloric Acid SCHEMBL30986707 | 0.98 | PDE4B (0.51) | PDE4BROCK2NTRK1NAMPTIDO1 | |
| SCHEMBL28089823 | 0.82 | NTRK1 (0.52) | PDE4BROCK2NTRK1IDO1 | |
| Hydrochloric Acid SCHEMBL30986722 | 0.80 | NTRK1 (0.51) | PDE4BROCK2NTRK1IDO1 | |
| SCHEMBL22968793 | 0.79 | ROCK2 (0.45) | PDE4BROCK2NAMPTIDO1DAO | |
| SCHEMBL22968941 | 0.79 | PDE4B (0.52) | PDE4BROCK2NAMPTIDO1AGXT | |
| SCHEMBL3300303 | 0.79 | TAAR1 (0.60) | IDO1AGXTDAOHCAR2TAAR1 | |
| SCHEMBL22969026 | 0.79 | PDE4B (0.55) | PDE4BROCK2NAMPTIDO1DAO | |
| SCHEMBL22968991 | 0.78 | NTRK1 (0.42) | PDE4BROCK2NTRK1IDO1AGXT | |
| Hydrochloric Acid SCHEMBL29467188 | 0.78 | IDO1 (0.46) | PDE4BROCK2NAMPTIDO1DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114206861-A | Fused heteroaryl compounds useful as RIPK1 inhibitors | 比西切姆有限公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2021029632-A1 | FUSED RING HETEROARYL COMPOUNDS AS RIPK1 INHIBITORS | BISICHEM CO., LTD. (KR) | 2021-02-18 | — | — | WO | disclosed |
| US-20210040115-A1 | FUSED RING HETEROARYL COMPOUNDS AS RIPK1 INHIBITORS | BISICHEM CO., LTD. (KR) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040115-A1 | FUSED RING HETEROARYL COMPOUNDS AS RIPK1 INHIBITORS | RIPK1, RIPK3, RIPK4 | PDE4B 4578/4885ROCK2 350/4885NTRK1 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.